The National Health Insurance Company announces that people suffering from migraines, pneumonia, bronchitis, diabetes and hypertension will have access, starting April 1, to new medicines compensated through the compulsory medical insurance funds, IPN reports.

Patients diagnosed with migraines can benefit from partial compensation for sumatriptanum, a drug intended to relieve symptoms in acute episodes.

In the case of children with pneumonia, acute or chronic bronchitis, cefprozilum powder for oral suspension will be fully compensated.

For patients with type 2 diabetes, the list of compensated drugs is extended with linagliptinum, which helps keep blood sugar levels under control.

Also, patients with hypertension will have access to a new combination preparation, lisinoprilum + amlodipinum, which facilitates the administration of treatment and contributes to blood pressure control.

Also, cetirizinum, used in the treatment of seasonal and perennial allergic rhinitis in children, will be fully compensated.

The extension of the list of compensated medicines was approved following the meeting of the Council for Compensated Medicines on March 14 and entered into force through a joint order of the Minister of Health and the Director General of the National Health Insurance Company.